Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

Abstract Background Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in patients with resectable colorectal cancer (CRC), non-small-cell lung...

Full description

Bibliographic Details
Main Authors: Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo, Kerry Fisher
Format: Article
Language:English
Published: BMJ Publishing Group 2017-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:http://link.springer.com/article/10.1186/s40425-017-0277-7

Internet

http://link.springer.com/article/10.1186/s40425-017-0277-7

Similar Items